TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10908898

Group type: EXPERIMENTAL
Intervention: Levetiracetam 1000 mg/day
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Levetiracetam 3000 mg/day
Number of subjects: 294

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Levetiracetam (both dosages combined)
Number of subjects: 294
Study: 8769497

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Anterior Mandibular Positioning (AMP) device
Number of subjects: 21

Group type: COMPARATOR
Intervention: Both treatments (CPAP and AMP)
Number of subjects: 21
Study: 1525702

Group type: EXPERIMENTAL
Intervention: Deflazacort (DFZ)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Prednisone (PDN)
Number of subjects: 29
Study: 3549597

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 30062946

Group type: COMPARATOR
Intervention: Single dose of 2.0 g of TXA orally two hours preoperatively (group A)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Single dose of TXA followed by 1.0 g orally three hours postoperatively (group B)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Single dose of TXA followed by 1.0 g three and nine hours postoperatively (group C)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Single dose of TXA followed by 1.0 g orally three, nine, and 15 hours postoperatively (group D)
Number of subjects: 200
Study: 28391391

Group type: EXPERIMENTAL
Intervention: Stretching to the point of pain (POP)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Stretching to the point of discomfort (POD)
Number of subjects: 22
Study: 26230270

Group type: EXPERIMENTAL
Intervention: 50 mg/day desvenlafaxine
Number of subjects: 1562

Group type: EXPERIMENTAL
Intervention: 100 mg/day desvenlafaxine
Number of subjects: 1562

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1562
Study: 23023151

Group type: EXPERIMENTAL
Intervention: Transperitoneal laparoscopic ureterolithotomy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Retroperitoneal laparoscopic ureterolithotomy
Number of subjects: 48
Study: 21095914

Group type: EXPERIMENTAL
Intervention: Laser acupuncture (AlGaAs laser, 650 nm, energy density of 2.4 J/cm2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional acupuncture (needles)
Number of subjects: 40
Study: 18413835

Group type: EXPERIMENTAL
Intervention: Doxercalciferol (10 microg orally, days 1-28) with docetaxel (35 mg/m2 i.v., days 1, 8, and 15)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo with docetaxel (35 mg/m2 i.v., days 1, 8, and 15)
Number of subjects: 70
Study: 15932141

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12950597

Group type: EXPERIMENTAL
Intervention: 3'SL 10 g/day
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 3'SL 20 g/day
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 10475152

Group type: EXPERIMENTAL
Intervention: Group A (16 children with blunted serum GH peak levels)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Group B (6 subjects with normal serum GH peak values)
Number of subjects: 22
Study: 7572258

Group type: EXPERIMENTAL
Intervention: Moclobemide (MOC; maximum dose 600 mg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Doxepin (DOX; maximum dose 250 mg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Moclobemide (MOC)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Doxepin (DOX)
Number of subjects: 56
Study: 1951126

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 56

Group type: COMPARATOR
Intervention: Hydrochlorothiazide or Enalapril (Control Group)
Number of subjects: 56
Study: 7036171

Group type: EXPERIMENTAL
Intervention: Pulses of methylprednisolone, immunosuppressive drugs and anticoagulants plus plasma exchanges for one to two months (PE+)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Pulses of methylprednisolone, immunosuppressive drugs and anticoagulants (Control)
Number of subjects: 14
Study: 30549127

Group type: EXPERIMENTAL
Intervention: Carbamazepine (single oral dose)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Brivaracetam (single oral dose)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tiagabine (single oral dose)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 15
Study: 28479493

Group type: EXPERIMENTAL
Intervention: Bilateral SEMS placement
Number of subjects: 133

Group type: COMPARATOR
Intervention: Unilateral SEMS placement
Number of subjects: 133
Study: 26087567

Group type: EXPERIMENTAL
Intervention: Jintian'ge capsule in addition to percutaneous kyphoplasty (PKP)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Percutaneous kyphoplasty (PKP)
Number of subjects: 69
Study: 23579320

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control conditions (acetaminophen and placebo)
Number of subjects: 0
Study: 22384545

Group type: EXPERIMENTAL
Intervention: Danhong Injection (DHI) 20 mL intravenously dripped in 250 mL 0.9% sodium chloride injection from 2-3 days before PCI to 3 days after PCI, once daily.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine medicines including loperamide injection, enteric coated aspirin, Betaloc, and routine rehydration therapy (Control group).
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Danhong Injection (DHI)
Number of subjects: 80
Study: 19455042

Group type: EXPERIMENTAL
Intervention: Propofol infusion at target plasma concentrations (0, 1.3, 1.7, 2.0, 2.4, 2.8 microg ml(‐1))
Number of subjects: 30
Study: 16963215

Group type: EXPERIMENTAL
Intervention: Daily cannabis users (N=18)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Non-daily cannabis users (N=20)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: All subjects (N=53)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Specimens with detectable cannabinoids
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Specimens screening positive for THC
Number of subjects: 38
Study: 15470284

Group type: EXPERIMENTAL
Intervention: Device to guide slow breathing
Number of subjects: 149

Group type: COMPARATOR
Intervention: Home blood pressure monitoring with simple written instructions
Number of subjects: 149
Study: 11168270

Group type: COMPARATOR
Intervention: Conventional denture (CD-group)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Implant-mucosa-borne overdenture on 2 IMZ implants (IMZ-group)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Mainly implant-borne overdenture retained by a transmandibular implant (TMI-group)
Number of subjects: 68
Study: 9923572

Group type: EXPERIMENTAL
Intervention: 100 mg ASA plain
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 100 mg ASA enteric-coated
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 40 mg ASA plain
Number of subjects: 36
Study: 8934981

Group type: EXPERIMENTAL
Intervention: Clonidine (5 micrograms/kg orally 2 hours before sedation)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Midazolam alone (Control group)
Number of subjects: 8
Study: 2748718

Group type: EXPERIMENTAL
Intervention: Two cycle ergometer exercise sessions and one bronchial hygiene treatment session per day (EX Group)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Three bronchial hygiene treatment sessions per day (PD Group)
Number of subjects: 17
Study: 668102

Group type: EXPERIMENTAL
Intervention: ICI 74,917
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 30448689

Group type: EXPERIMENTAL
Intervention: Reward Group (competing rewards established by linking CS+ option to high rewards and CS- option to low rewards during acquisition and test)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Initial-Reward Group (rewards present during acquisition, but discontinued during test)
Number of subjects: 223

Group type: COMPARATOR
Intervention: No-Reward Group (rewards completely absent)
Number of subjects: 223
Study: 26711658

Group type: EXPERIMENTAL
Intervention: Yokukansan (YKS) 7.5 g/day
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 25897153

Group type: EXPERIMENTAL
Intervention: ABVD
Number of subjects: 264

Group type: COMPARATOR
Intervention: Stanford V
Number of subjects: 264
Study: 25453519

Group type: EXPERIMENTAL
Intervention: Therapeutic yoga (16 sessions, twice a week for 8 weeks)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 47
Study: 22810441

Group type: EXPERIMENTAL
Intervention: Pilot randomized study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pilot studies
Number of subjects: 0
Study: 18829015

Group type: EXPERIMENTAL
Intervention: recombinant human FSH plus hCG after GnRH agonist treatment
Number of subjects: 87

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 87
Study: 17697815

Group type: EXPERIMENTAL
Intervention: Triple therapy (aspirin, clopidogrel, and cilostazol)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dual therapy (aspirin and clopidogrel)
Number of subjects: 20
Study: 15530674

Group type: EXPERIMENTAL
Intervention: HB‐AS04 (2 doses at 0 and 6 months)
Number of subjects: 1303

Group type: COMPARATOR
Intervention: Comparator vaccine (3 doses at 0, 1, and 6 months)
Number of subjects: 1303
Study: 11586161

Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound therapy (20-minute daily applications at the site of the nonunion)
Number of subjects: 29
Study: 10558395

Group type: EXPERIMENTAL
Intervention: Cluster assignment of schools
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 7924650

Group type: EXPERIMENTAL
Intervention: Retinamide II (RII) suppository intravaginally, once daily for 50 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo, once daily for 50 days
Number of subjects: 0
Study: 2476933

Group type: EXPERIMENTAL
Intervention: Cordocentesis
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravascular transfusion
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cordocentesis with anterior placenta
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cordocentesis with non-anterior placenta
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cordocentesis vs Intravascular transfusion
Number of subjects: 50
Study: 4877801

Group type: EXPERIMENTAL
Intervention: Micronized flumedroxone 10 mg t.d.s.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31335669

Group type: EXPERIMENTAL
Intervention: Prison-based cognitive behavioral rehabilitation intervention (PCBRI)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 45
Study: 28195931

Group type: EXPERIMENTAL
Intervention: Antipsychotic medication adherence
Number of subjects: 35

Group type: COMPARATOR
Intervention: Poor medication adherence
Number of subjects: 35
Study: 25883244

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (20 minutes to motor cortex at 2 mA) for five consecutive days before cognitive behavioural management.
Number of subjects: 135

Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (identical electrode position, stimulator switched off after 30 seconds) for five consecutive days before cognitive behavioural management.
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural management (four week multidisciplinary programme of 80 hours).
Number of subjects: 135
Study: 23088175

Group type: EXPERIMENTAL
Intervention: Loss-framed messages targeting psychological health
Number of subjects: 96

Group type: COMPARATOR
Intervention: Gain-framed messages targeting psychological health
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Loss-framed messages
Number of subjects: 96

Group type: COMPARATOR
Intervention: Gain-framed messages
Number of subjects: 96
Study: 21947753

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) 50 mg/kg bolus followed by 15 mg/kg/h infusion and another 50 mg/kg into the bypass circuit
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 160
Study: 18649974

Group type: EXPERIMENTAL
Intervention: Intravenous glutamine dipeptide
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 16824141

Group type: EXPERIMENTAL
Intervention: Tacrolimus and MMF
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cyclosporine and MMF
Number of subjects: 120

Group type: COMPARATOR
Intervention: Tacrolimus (control)
Number of subjects: 120

Group type: COMPARATOR
Intervention: MMF-free control (Tacrolimus and corticosteroids)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: MPA pharmacokinetics with tacrolimus
Number of subjects: 120
Study: 12738555

Group type: EXPERIMENTAL
Intervention: Topical betaxolol
Number of subjects: 95

Group type: COMPARATOR
Intervention: Topical timolol
Number of subjects: 95
Study: 11270020

Group type: EXPERIMENTAL
Intervention: Continuous infusion of propofol
Number of subjects: 25

Group type: COMPARATOR
Intervention: Intermittent boluses of midazolam
Number of subjects: 25
Study: 9293933

Group type: EXPERIMENTAL
Intervention: Butyric acid enemas (40 mmol) twice per day for two weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 7994793

Group type: EXPERIMENTAL
Intervention: Single instillation of hydroxypropylcellulose-doxorubicin (20 mg/20 ml)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combined intravesical instillation of hydroxypropylcellulose-doxorubicin and local hyperthermia
Number of subjects: 31
Study: 3176836

Group type: EXPERIMENTAL
Intervention: Rectal administration of 0.5 mg/kg midazolam and 0.05 mg/kg atropine
Number of subjects: 202

Group type: COMPARATOR
Intervention: Intramuscular administration of 0.15 mg/kg midazolam and 0.02 mg/kg atropine
Number of subjects: 202
Study: 31700547

Group type: EXPERIMENTAL
Intervention: Passive hallux adduction
Number of subjects: 45

Group type: COMPARATOR
Intervention: Pre-passive hallux adduction
Number of subjects: 45
Study: 28346865

Group type: EXPERIMENTAL
Intervention: Active 20 Hz rTMS applied to the dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham rTMS applied to the dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 0
Study: 25490277

Group type: EXPERIMENTAL
Intervention: Deep sleep disruption via auditory stimuli
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal deep sleep
Number of subjects: 14
Study: 24109189

Group type: EXPERIMENTAL
Intervention: Losartan 100 mg + HCTZ 25 mg
Number of subjects: 59

Group type: COMPARATOR
Intervention: Bisoprolol 10 mg + HCTZ 25 mg
Number of subjects: 59
Study: 22074958

Group type: EXPERIMENTAL
Intervention: Chlorpromazine 100 mg simple dose formulation
Number of subjects: 57

Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 57
Study: 18202711

Group type: EXPERIMENTAL
Intervention: Oblique injection technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard injection technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 0
Study: 16442666

Group type: EXPERIMENTAL
Intervention: Affective priming paradigm in the picture‐picture naming task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Affective priming effects from the naming task
Number of subjects: 0
Study: 14606135

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) with factor V Leiden mutation
Number of subjects: 0
Study: 10678615

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (2,000 microg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9076423

Group type: EXPERIMENTAL
Intervention: Pipelle (P)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Cytospat (C)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: D&C
Number of subjects: 365
Study: 7687608

Group type: COMPARATOR
Intervention: Histamine challenge (1 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Allergen challenge (increasing doses)
Number of subjects: 8
Study: 3307584

Group type: EXPERIMENTAL
Intervention: Biosynthetic human insulin (0.2 U/kg body weight)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Purified pork insulin (0.2 U/kg body weight)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Biosynthetic human insulin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Purified pork insulin
Number of subjects: 10
Study: 31992249

Group type: EXPERIMENTAL
Intervention: Physical activity and sedentary time in South Asian and white British children
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Weekends vs weekdays
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Spring vs winter
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: High birth weight
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Older mothers
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Income levels
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Gender differences
Number of subjects: 342
Study: 30403574

Group type: EXPERIMENTAL
Intervention: Alirocumab (75 mg subcutaneously every 2 weeks)
Number of subjects: 18924

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18924

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 18924
Study: 26981608

Group type: EXPERIMENTAL
Intervention: Comprehensive oral health care (oral health examination, oral health education, topical fluoride application, dental treatment)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Control group (oral health examination only)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Comprehensive oral health care
Number of subjects: 357
Study: 26102260

Group type: EXPERIMENTAL
Intervention: Kettlebell training (KB) group (n = 9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Circuit weight-training (CWT) control group (n = 8)
Number of subjects: 17
Study: 24081999

Group type: EXPERIMENTAL
Intervention: Sports-related TBI admissions
Number of subjects: 3878

Group type: COMPARATOR
Intervention: ED visits for sports-related TBIs
Number of subjects: 3878
Study: 20580423

Group type: EXPERIMENTAL
Intervention: Vitamin C (1000 mg) and Vitamin E (400 IU) daily until delivery
Number of subjects: 762

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 762
Study: 18648200

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) treatment, mean dose 158 mg, duration at least 3 months
Number of subjects: 96

Group type: COMPARATOR
Intervention: Aspirin (ASA) treatment
Number of subjects: 96
Study: 16848374

Group type: EXPERIMENTAL
Intervention: Konstanz method of moral dilemma discussion (KMDD), 90 minutes once a week for 6 weeks
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group discussion on non-ethical topics, once a week for 6 weeks
Number of subjects: 83
Study: 14717538

Group type: EXPERIMENTAL
Intervention: Aerobic athletes
Number of subjects: 140

Group type: COMPARATOR
Intervention: Physical education female students
Number of subjects: 140

Group type: COMPARATOR
Intervention: Non-sportive women
Number of subjects: 140
Study: 11005755

Group type: EXPERIMENTAL
Intervention: Topical application of lidocaine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8927673

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 1832607

Group type: EXPERIMENTAL
Intervention: Picotamide monohydrate, 1200 mg daily three days before surgery, tapering to 900 mg daily postoperatively
Number of subjects: 32
Study: 6624525

Group type: EXPERIMENTAL
Intervention: Dimeglumine iocarmate (Dimerex)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Conray Meglumin
Number of subjects: 374

Group type: COMPARATOR
Intervention: Sodium‐calcium‐meglumine metrizoate (Isopaque Cerebral)
Number of subjects: 374
Study: 30249195

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (300 mg)
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2400
Study: 27259709

Group type: EXPERIMENTAL
Intervention: EP217609 (1, 3, or 10 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 24977250

Group type: COMPARATOR
Intervention: Autogenous bone blocks (AB group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Equine bone blocks (XB group)
Number of subjects: 40
Study: 23311022

Group type: EXPERIMENTAL
Intervention: One-stop cholecystectomy clinics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lean thinking principles
Number of subjects: 0
Study: 20071642

Group type: EXPERIMENTAL
Intervention: High fiber intake group (highest 10%)
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Low fiber intake group (lowest 10%)
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Average fiber intake group (middle 80%)
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 264)
Number of subjects: 543

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Overall fiber intake
Number of subjects: 543
Study: 17324094

Group type: EXPERIMENTAL
Intervention: Educational program focused on mammography delivered by a lay health advisor
Number of subjects: 775

Group type: COMPARATOR
Intervention: Physician letter/brochure focusing on Pap tests
Number of subjects: 775

Group type: EXPERIMENTAL
Intervention: High-risk group for developing cervical cancer
Number of subjects: 775

Group type: EXPERIMENTAL
Intervention: Low-risk group for developing cervical cancer
Number of subjects: 775
Study: 16392983

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interpersonal psychotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) and interpersonal psychotherapy
Number of subjects: 0
Study: 12080869

Group type: EXPERIMENTAL
Intervention: Extended Glasgow Outcome Scale (GOSE)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Functional Status Examination (FSE)
Number of subjects: 61
Study: 10458260

Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Carboplatin
Number of subjects: 24